공고 • Mar 04
GeneBioTech Co. ,Ltd, Annual General Meeting, Mar 26, 2026 GeneBioTech Co. ,Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 489, yeonggyudaesa-ro, gyeryong-myeon, chungcheongnam-do, gongju South Korea 공고 • Feb 10
GeneBioTech Co. ,Ltd announces Annual dividend GeneBioTech Co.,Ltd announced Annual dividend of KRW 50.0000 per share, ex-date on December 29, 2025 and record date on December 31, 2025. New Risk • Feb 09
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.1% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩39.6b market cap, or US$27.1m). New Risk • Aug 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (₩47.8b market cap, or US$34.4m). Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to ₩5,550, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 12% over the past three years. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩4,145, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 23% over the past three years. Reported Earnings • Mar 19
Full year 2024 earnings released: EPS: ₩333 (vs ₩301 in FY 2023) Full year 2024 results: EPS: ₩333 (up from ₩301 in FY 2023). Revenue: ₩83.0b (up 4.4% from FY 2023). Net income: ₩2.87b (up 11% from FY 2023). Profit margin: 3.5% (up from 3.3% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. 공고 • Feb 22
GeneBioTech Co. ,Ltd, Annual General Meeting, Mar 24, 2025 GeneBioTech Co. ,Ltd, Annual General Meeting, Mar 24, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 489, yeonggyudaesa-ro, gyeryong-myeon, chungcheongnam-do, gongju South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩28.8b market cap, or US$20.1m). Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩105 (vs ₩90.00 in 3Q 2023) Third quarter 2024 results: EPS: ₩105 (up from ₩90.00 in 3Q 2023). Revenue: ₩20.4b (up 2.4% from 3Q 2023). Net income: ₩902.9m (up 16% from 3Q 2023). Profit margin: 4.4% (up from 3.9% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 20
Full year 2023 earnings released: EPS: ₩301 (vs ₩177 in FY 2022) Full year 2023 results: EPS: ₩301 (up from ₩177 in FY 2022). Revenue: ₩79.5b (down 4.0% from FY 2022). Net income: ₩2.59b (up 70% from FY 2022). Profit margin: 3.3% (up from 1.8% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩90.00 (vs ₩25.00 loss in 3Q 2022) Third quarter 2023 results: EPS: ₩90.00 (up from ₩25.00 loss in 3Q 2022). Revenue: ₩20.0b (down 11% from 3Q 2022). Net income: ₩777.9m (up ₩994.4m from 3Q 2022). Profit margin: 3.9% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • May 21
First quarter 2023 earnings released: EPS: ₩80.00 (vs ₩42.00 in 1Q 2022) First quarter 2023 results: EPS: ₩80.00 (up from ₩42.00 in 1Q 2022). Revenue: ₩19.4b (up 1.3% from 1Q 2022). Net income: ₩686.6m (up 89% from 1Q 2022). Profit margin: 3.5% (up from 1.9% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 22
Full year 2022 earnings released: EPS: ₩177 (vs ₩56.00 loss in FY 2021) Full year 2022 results: EPS: ₩177 (up from ₩56.00 loss in FY 2021). Revenue: ₩82.8b (up 32% from FY 2021). Net income: ₩1.52b (up ₩2.01b from FY 2021). Profit margin: 1.8% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 11
Third quarter 2022 earnings released: ₩25.00 loss per share (vs ₩14.00 loss in 3Q 2021) Third quarter 2022 results: ₩25.00 loss per share (further deteriorated from ₩14.00 loss in 3Q 2021). Revenue: ₩22.4b (up 45% from 3Q 2021). Net loss: ₩216.5m (loss widened 84% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩30.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 05 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%). Reported Earnings • Nov 16
Third quarter 2021 earnings released: ₩14.00 loss per share (vs ₩65.00 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.5b (down 8.2% from 3Q 2020). Net loss: ₩117.6m (down 121% from profit in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment improved over the past week After last week's 21% share price gain to ₩6,000, the stock is trading at a trailing P/E ratio of 57.1x, up from the previous P/E ratio of 47x. This compares to an average P/E of 50x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years were flat. Is New 90 Day High Low • Feb 24
New 90-day low: ₩5,110 The company is down 18% from its price of ₩6,230 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. 공고 • Feb 16
Genebiotech Co., Ltd., Annual General Meeting, Mar 25, 2021 Genebiotech Co., Ltd., Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Feb 01
New 90-day low: ₩5,390 The company is down 12% from its price of ₩6,140 on 03 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period. Is New 90 Day High Low • Jan 12
New 90-day low: ₩5,450 The company is down 7.0% from its price of ₩5,870 on 14 October 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩30.00 Per Share Will be paid on the 6th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.5% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.3%). Reported Earnings • Nov 19
Third quarter 2020 earnings released: EPS ₩65.00 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩16.8b (up 17% from 3Q 2019). Net income: ₩557.4m (up 283% from 3Q 2019). Profit margin: 3.3% (up from 1.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Sep 24
New 90-day low: ₩5,250 The company is down 8.0% from its price of ₩5,730 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.